Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06053437
Other study ID # 2022PI198
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2023
Est. completion date September 1, 2023

Study information

Verified date September 2023
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Predicting the outcome of pituitary surgery, particularly the risk of complications, is a critical determinant in selecting the appropriate treatment modality for patients. To date, only a limited number of risk factors have been identified for complications following pituitary surgery, including tumor size, younger age, and previous surgical intervention. Furthermore, existing studies have demonstrated that prolactin levels can serve as a surrogate marker for assessing pituitary function, specifically revealing associations between elevated prolactin levels and anterior pituitary insufficiencies. In a retrospective study on the "HYP'OP" cohort, the aim of the study is to identify predictive factors for both surgical outcomes and complications.


Recruitment information / eligibility

Status Completed
Enrollment 211
Est. completion date September 1, 2023
Est. primary completion date July 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Transsphenoidal pituitary surgery at Nancy University Hospital (France) between 2012 and 2022 for a pituitary adenoma. Exclusion Criteria: - No 4 month evaluation.

Study Design


Locations

Country Name City State
France Centre Hospitalier Régional Universitaire de Nancy Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Is hypoprolactinemia at the 4-month follow-up is correlated with the number of affected pituitary axes? Patients were stratified into four groups using the same criteria as outlined in Outcome 3. Within 6 months after surgery
Primary Risk factors associated with complications Risk factors associated with complications arising from surgery, specifically targeting the incidence of de-novo, clinically significant pituitary insufficiencies Within 6 months after surgery
Secondary Factors predictive of the 'success' of surgery Patients were stratified into groups based on surgical indications. The first group consisted of non-secreting, non-compressive adenomas without preoperative insufficiency or hyperprolactinemia, with success defined as absence of new insufficiency and no MRI-detected residual tissue. The second group was similar to the first but included disconnection hyperprolactinemia, and success was defined by the absence of new insufficiency and hyperprolactinemia regression. The third group involved non-secreting adenomas with at least one preoperative axis deficiency, irrespective of hyperprolactinemia, with success defined as restoration of at least one deficient axis without new insufficiency. The fourth group included secreting adenomas, with success defined as hypersecretion regression. The fifth group involved adenomas operated on for their compressive effect on the optic pathways, with or without hyperprolactinemia, and success was defined as no compression observed on follow-up MRI. Within 6 months after surgery
Secondary Is immediate postoperative hypoprolactinemia predictive of the onset of a new, clinically significant hormonal insufficiency? patients were stratified into four groups based on immediate postoperative prolactin levels: Group 1 consisted of severe hypoprolactinemia; Group 2 included moderate hypoprolactinemia; Group 3 involved normal prolactin levels, defined by prolactin levels between 5 and 20 ng/ml; and Group 4 comprised hyperprolactinemia, defined by prolactin levels > 20 ng/ml. It should be noted that these instances of hyperprolactinemia are theoretically all disconnection hyperprolactinemias, as patients with lactotroph adenomas were excluded from this analysis. Patients under treatment for hyperprolactinemia were also excluded. Within 6 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Completed NCT01689064 - Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection N/A
Recruiting NCT04611685 - Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas N/A
Completed NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW Phase 1
Recruiting NCT02709863 - Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests N/A
Completed NCT01465672 - Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis N/A
Terminated NCT00798057 - Proton Radiation Therapy for Pituitary Adenoma N/A
Completed NCT01504399 - Rhinological Outcomes in Endonasal Pituitary Surgery
Recruiting NCT01556230 - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Completed NCT04074642 - OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study. N/A
Recruiting NCT04621565 - Hydrocortisone Use During Peri-operation for Pituitary Adenomas N/A
Completed NCT04076046 - Multicentric Prospective Validation of the Zurich Pituitary Score
Not yet recruiting NCT03714763 - Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) N/A
Recruiting NCT05822817 - Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery Phase 4
Recruiting NCT03164148 - Heart Rate Variability (HRV) in Pituitary Adenoma N/A
Completed NCT04284605 - Effects Exercise Training in Patients With Pituitary Adenoma N/A
Terminated NCT03515603 - Endocrine Outcome of Surgery for Pituitary Adenoma N/A
Not yet recruiting NCT04863456 - Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement N/A
Active, not recruiting NCT03465618 - A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors Phase 1
Completed NCT02727686 - Post-Operative Water Load Following Transsphenoidal Pituitary Surgery N/A